CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AstraZeneca plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AstraZeneca plc
1 Francis Crick Avenue
Cambridge Biomedical Campus
Phone: +44 2073045000p:+44 2073045000 CAMBRIDGE, CB2 0AA  United Kingdom Ticker: AZNAZN
Business Summary
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes-YesYes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board MichelDemare 67 4/27/2023 9/1/2019
Chief Executive Officer, Executive Director PascalSoriot 64 10/1/2012 10/1/2012
Chief Financial Officer, Executive Director AradhanaSarin 8/1/2021 8/1/2021
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ASTRAZENECA PLC
ASTRAZENECA PLC
ASTRAZENECA SWEDEN INVESTMENTS LIMITED 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS UK
57 additional Subsidiary records available in full report.

Business Names
Business Name
AAPM SARL
Acerta Pharma B.V.
Acerta Pharma LLC
280 additional Business Names available in full report.

General Information
Number of Employees: 89,900 (As of 12/31/2023)
Outstanding Shares: 1,550,303,887 (As of 10/31/2024)
Shareholders: 66,385
Stock Exchange: LON
Federal Tax Id: 510112321
Fax Number: +44 2076048151


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024